PMS Registry
Company Name
Novartis (Taiwan) Co., Ltd.
Protocol Number
Title of Study
An observational, multi-center, prospective, open-label study to assess effectiveness, safety and tolerability of treatment with single pill combination of vildagliptin plus metformin(50mg/500mg, 50mg/850mg, 50mg/1000mg film-coated tablets)in type 2 diabetes mellitus patients in a real-world setting
Primary Objective
To assess the effectiveness of vildagliptin plus metformin SPC for the treatment in T2DM patients uncontrolled with metformin monotherapy as measured by change of HbA1c after treatment period of 24±6 week.
Number of Sites
Period of Study
From:January 29, 2015 to:March, 2017
Number of Patients
IRB Approval Date
December 31, 2014
Publication Plan / Date
September, 2017